Pioneering a New Era: Bionano Genomics’ OGM Receives Preliminary CMS Payment Determination
In a significant development for genomic medicine, Bionano Laboratories, a subsidiary of Bionano Genomics, Inc. (NASDAQ: BNGO), announced on September 15, 2025, that the Centers for Medicare & Medicaid Services (CMS) has published a preliminary payment determination for a new Category I Current Procedural Terminology (CPT) code. This code pertains to the use of optical genome mapping (OGM) in the analysis of cytogenomic disorders revolutionizing how structural and copy number variations associated with constitutional genetic disorders are diagnosed and treated.
The move marks an important step forward in the integration of advanced genetic testing into standard healthcare practices. CMS has decided to crosswalk the new CPT code to a previously established proprietary laboratory analyte (PLA) code for OGM, which comes with a pricing benchmark of $1,263.53. This figure is noteworthy as it sets a new standard that is $363.53 higher than the current price for code 81228, which covers microarray tests at $900, and $103.53 higher than code 81229, priced at $1,160.
The implications of this development go beyond mere numbers. As the healthcare landscape increasingly embraces precision medicine, the ability to detect genetic abnormalities more efficiently can heavily influence treatment paths for millions of patients grappling with genetic disorders. OGM not only enhances the accuracy of genetic testing but also provides a more comprehensive understanding of a patient’s genetic makeup, leading to better-informed clinical decisions.
Bionano Genomics has positioned itself at the forefront of this genetic revolution. With 3.441 million shares outstanding and a current market price of $3.88, the company continues to garner attention from stakeholders and investors eager to capitalize on the advancements in genetic testing technologies. The positive CMS preliminary determination adds to Bionano’s allure, particularly as the healthcare industry leans towards innovation that offers improved patient outcomes and cost-effective solutions.
Investors and healthcare professionals alike are watching with keen interest as Bionano’s OGM technology paves the way for more effective disease management and treatment protocols. The potential impact on public health cannot be overstated, presenting an opportunity to transform how genetic disorders are understood and treated on a global scale.
As Bionano Genomics continues to build on its legacy through technological innovations and strategic regulatory approvals, the preliminary payment determination by CMS stands as a testament to the growing recognition of optical genome mapping within the healthcare system. This development is not just a milestone for the company; it heralds a new era in genetic testing that could redefine clinical practice and improve the lives of countless individuals facing the challenges of genetic disorders.
In an era where personalized medicine is the future, Bionano is not just participating in the conversation but leading it one genomic breakthrough at a time.
Comments